Skip to main content
SpringerLink
Log in

Is temsirolimus more safe and effective than interferon α for the treatment of advanced renal cell carcinoma?

  • Practice Point
  • Published:

From Nature Clinical Practice Urology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dutcher JP et al. (2007) Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol 25 (Suppl): 5033

    Google Scholar 

  2. Motzer RJ et al. (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530–2540

    Article  CAS  Google Scholar 

  3. Motzer RJ et al. (2000) Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 18: 1928–1935

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Murphy, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. A-R Golshayan is a Fellow in the Department of Hematology and Medical Oncology, and RM Bukowski is a Professor of Medicine and the Director of Experimental Therapeutics at the Cleveland Clinic Taussig Cancer Center, The Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.,

    Ali-Reza Golshayan & Ronald M Bukowski

Authors
  1. Ali-Reza Golshayan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronald M Bukowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ronald M Bukowski.

Ethics declarations

Competing interests

Ronald M Bukowski is a consultant for, is on a speakers' bureau for, and has received grant/research support from Bayer, Genentech, Pfizer and Wyeth. He is also a consultant for Novartis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Golshayan, AR., Bukowski, R. Is temsirolimus more safe and effective than interferon α for the treatment of advanced renal cell carcinoma?. Nat Rev Urol 4, 586–587 (2007). https://doi.org/10.1038/ncpuro0915

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0915

  • Springer Nature Limited

Search

Navigation